Blog
GLP-3 vs Tirzepatide vs Semaglutide: Research Peptide Comparison
For research use only. Material is supplied as a lyophilized reference compound with HPLC purity verification.
- Key Facts at a Glance
- The three peptides at a glance
- Semaglutide: the category-defining GLP-1
- Tirzepatide: dual agonism raises the ceiling
- GLP-3: triple agonism and the glucagon difference
Last updated: 19 April 2026 · Reviewed by the Emirates Peptides Research Team · 8-minute read
If you are comparing GLP-1-class research peptides in the UAE, three names dominate the conversation: GLP-3, Tirzepatide (Mounjaro), and Semaglutide (Ozempic, Wegovy). They are related but not interchangeable. This comparison breaks down what each one actually does, what the Phase 2 and Phase 3 data show, and when biohackers and metabolic researchers reach for one over the others.
02 · Three
The three peptides at a glance
| Feature | Semaglutide | Tirzepatide | GLP-3 |
|---|---|---|---|
| Receptor targets | GLP-1 only | GIP + GLP-1 | GIP + GLP-1 + Glucagon |
| Brand names | Ozempic, Wegovy, Rybelsus | Mounjaro, Zepbound | (Investigational) LY3437943 |
| Half-life | ~7 days | ~5 days | ~6 days |
| Typical weekly research dose | 0.25–2.4 mg | 2.5–15 mg | 2–12 mg |
| Phase 2/3 top-dose weight reduction (48 wk) | ~14.9% | ~20.9% | ~24.2% |
| Approval status (Apr 2026) | FDA approved | FDA approved | Investigational only |
| Glucagon / metabolic-rate effect | Minimal | Minimal | Yes — increases REE |
03 · Semaglutide
Semaglutide: the category-defining GLP-1
Latest research insights. No spam, ever.
Semaglutide is the one most people have heard of — under the brand names Ozempic (type-2 diabetes), Wegovy (obesity), and Rybelsus (oral formulation). Mechanistically it is the simplest of the three: a single-receptor agonist acting only on the GLP-1 receptor. That single-target profile produces reliable appetite suppression and delayed gastric emptying but without the additional metabolic levers of the newer compounds.
Phase 3 data (STEP trials) show average weight reduction around 14.9% at 68 weeks in non-diabetic adults with obesity. The side-effect profile is well characterized — nausea, diarrhea, and constipation lead the list, with most events concentrated in dose-titration weeks.
For researchers, Semaglutide remains the reference compound against which newer peptides are benchmarked. If your research question involves pure GLP-1 receptor biology, this is the cleaner tool.
04 · Tirzepatide
Tirzepatide: dual agonism raises the ceiling
Tirzepatide (Mounjaro for type-2 diabetes, Zepbound for obesity) added a second receptor: GIP. The theoretical basis was that GIP contributes to insulin sensitivity and may dampen some of the gastrointestinal side effects of pure GLP-1 activation. The data largely supports this hypothesis.
SURMOUNT-1 showed ~20.9% mean weight reduction at the 15 mg weekly dose across 72 weeks — approaching bariatric-surgery outcomes without surgery. The real-world impact has been enormous. “Mounjaro Dubai” is now one of the highest-volume peptide-related search queries in the UAE, with an estimated 1,900 monthly searches.
From a mechanism standpoint, Tirzepatide is a true dual agonist, not a GLP-1 with a bonus molecule bolted on. GIP receptor activation occurs at physiologic potency, and the clinical signatures — both the enhanced weight loss and the better-tolerated dose escalation — reflect genuinely dual pharmacology.
05 · GLP-3
GLP-3: triple agonism and the glucagon difference
GLP-3 is the newest of the three and the one that has changed what researchers think is possible. By adding glucagon-receptor activation to the existing GIP + GLP-1 framework, GLP-3 does something the first two cannot: it increases resting energy expenditure.
This is the piece biohackers in Dubai and across the UAE have paid attention to. Appetite suppression without metabolic-rate support still leaves research subjects fighting the metabolic adaptation that occurs during any caloric deficit. GLP-3’s glucagon component counteracts that adaptation to some extent, producing Phase 2 weight-reduction figures around 24.2% at 48 weeks — numerically superior to both Semaglutide and Tirzepatide.
GLP-3 remains investigational as of April 2026. Phase 3 trials are in progress. For UAE researchers, this status means GLP-3 is exclusively available through research-peptide suppliers rather than pharmacies — and the quality standards vary dramatically between suppliers. See our complete GLP-3 UAE guide for what to verify before purchasing.
06 · Peptide
Which peptide fits which research question?
Choose Semaglutide if:
- Your research question involves isolated GLP-1 receptor biology.
- You need an FDA-approved reference compound for benchmarking.
- You are working on glucose-regulation protocols rather than maximum weight-loss magnitude.
Choose Tirzepatide if:
- You need an approved dual-agonist reference.
- Your protocol requires better gastrointestinal tolerability than pure GLP-1.
- You are studying insulin-sensitivity mechanisms in addition to appetite.
Choose GLP-3 if:
- Maximum weight-reduction magnitude is the primary outcome.
- You are studying the contribution of glucagon signaling to whole-body energy metabolism.
- You are designing body-composition protocols where resting-metabolic-rate support matters.
07 · Quality
Quality standards apply equally to all three
Regardless of which peptide your research protocol calls for, the quality threshold is identical:
- HPLC purity ≥99%
- Mass-spectrometry sequence confirmation
- Lyophilization under inert atmosphere
- Batch-specific Certificate of Analysis available on request
- Cold-chain delivery (critical in UAE summer temperatures)
Emirates Peptides supplies all three compounds — Semaglutide, Tirzepatide, and GLP-3 — to this standard, with same-day cold-chain delivery across Dubai and next-day across all seven emirates.
08 · Questions
Frequently asked questions
Is GLP-3 stronger than Mounjaro?
In Phase 2 comparisons at top doses, GLP-3 produced greater weight reduction (~24.2% vs ~20.9%) and added a glucagon-receptor effect on resting energy expenditure that Tirzepatide lacks. “Stronger” depends on the outcome measured; for weight-loss magnitude, GLP-3 currently leads.
Is Ozempic the same as Wegovy?
Both contain Semaglutide as the active ingredient. Ozempic is the brand for type-2 diabetes at lower doses; Wegovy is the same molecule at higher doses approved for obesity. From a research-peptide standpoint, both are simply “Semaglutide” at different concentrations.
Can I switch from Semaglutide to GLP-3 directly?
Published switch protocols are limited. Research subjects reportedly undergo a brief washout period before starting the new peptide at its standard introductory dose rather than matching the prior compound dose. Protocol design is the responsibility of the qualified research professional.
Which has the worst side effects?
All three share the same GI-dominant side-effect profile: nausea, diarrhea, and vomiting are leading events. Semaglutide and GLP-3 report nausea rates in the 30–40% range at top doses; Tirzepatide is often reported as slightly better tolerated due to its GIP component.
Where do UAE buyers typically source these peptides?
Approved formulations of Semaglutide and Tirzepatide are available through UAE pharmacies by prescription. GLP-3, being investigational, is available exclusively through research-peptide suppliers. Quality verification matters enormously in this market. See our GLP-3 UAE guide for sourcing criteria.
Explore Research-Grade Peptides
HPLC-verified, lab-tested peptides for your scientific research. Fast delivery across the UAE.
Browse All PeptidesRelated Articles
Selected Research References
Selected scientific references for research context only. Products remain for laboratory research use and are not for human use.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
- Tirzepatide Once Weekly for the Treatment of Obesity
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- Once-weekly cagrilintide for weight management in people with overweight and obesity
Emirates Peptides Research Team
A dedicated coalition of biochemists and clinical researchers focusing on advanced peptide synthesis and pharmacological applications. All data is verified against current clinical trials.
